[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541722":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":48,"centralContacts":53,"locations":62,"responsibleParty":83,"collaborators":10,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":10,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":10,"studyType":99,"phases":10,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,19],{"label":9,"type":10,"description":11,"interventionNames":12},"HAIC+Len+PD-1 inhibitor group",null,"HAIC combined with Lenatinib and PD-1 inhibitor group",[13,14,15,16,17,18],"Procedure: Hepatic arterial infusion chemotherapy","Drug: Lenvatinib","Drug: Tislelizumab","Drug: Toripalimab","Drug: Sintilimab","Drug: Camrelizumab",{"label":20,"type":10,"description":21,"interventionNames":22},"Len group","Lenvatinib alone",[14],[24,29,34,38,42,45],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"PROCEDURE","Hepatic arterial infusion chemotherapy","Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg\u002Fm2 oxaliplatin from hour 0 to 2 on day 1400 mg\u002Fm2 leucovorin from hour 2 to 4 on day 1, and 400 mg\u002Fm2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg\u002Fm2 fluorouracil over 46 h on days 1 and 2.",[9],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"DRUG","Lenvatinib","12 mg (body weight ≥60 kg) , 8 mg (body weight \\\u003C60 kg) orally once a day",[9,20],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"Tislelizumab","200mg intravenously every 3 weeks",[9],{"type":30,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"Toripalimab","240mg intravenously every 3 weeks",[9],{"type":30,"name":43,"description":36,"armGroupLabels":44,"otherNames":10},"Sintilimab",[9],{"type":30,"name":46,"description":36,"armGroupLabels":47,"otherNames":10},"Camrelizumab",[9],[49],{"name":50,"affiliation":51,"role":52},"Feng Duan, MD","Chinese PLA General Hospital","PRINCIPAL_INVESTIGATOR",[54,59],{"name":55,"role":56,"phone":57,"phoneExt":10,"email":58},"Qunfang Zhou, MD","CONTACT","86 19868000115","zhouqun988509@163.com",{"name":50,"role":56,"phone":60,"phoneExt":10,"email":61},"86 13910984586","duanfeng@vip.sina.com",[63],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Chinese PLA General hospital","RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":72,"coordinates":73},"Point",[74,75],116.39723,39.9075,{"lat":75,"lon":74},[78,81],{"name":79,"role":56,"phone":80,"phoneExt":10,"email":58},"Qunfang Zhou, Md","8619868000115",{"name":50,"role":56,"phone":82,"phoneExt":10,"email":61},"8613910984586",{"type":52,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Zhou Qunfang","Clinical Professor","100541722","haic-combined-with-lenvatinib-and-pd-1-inhibitor-in-infiltrative-hepatocellular-carcinoma-100541722",false,"NCT06333561","HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma","Efficacy of HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma: an Observational, Real-world Study","Inclusion Criteria:\n\n1. primary infiltrative HCC according to MRI or CT imaging characteristics.\n2. Child-Pugh class A or B, and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.\n3. Lenvatinib as initial treatment.\n4. patients received HAIC and PD-1 inhibitor in HAIC+Len+PD-1 group, patients received Lenvatinib alone in Len group.\n5. no history of other malignancies.\n6. no tumor thrombus in the atrium or vena cava.\n\nExclusion Criteria:\n\n1. HCC with tumor capsule.\n2. under 18 years or over 75 years.\n3. TACE as initial treatment.\n4. sorafenib or other systemic therapy with or without PD-1 inhibitor following HAIC.\n5. incomplete tumor imaging data.\n6. lost to follow-up after treatment within three months.","ALL","18 Years","75 Years",{"count":97,"type":98},300,"ESTIMATED","OBSERVATIONAL","Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC). However, the evidence for infiltrative is limited. In this study, we aimed to describe the efficacy and safety of lenvatinib and PD-1 inhibitor with HAIC plus lenvatinib for infiltrative HCC.",[102,31,103,104],"Hepatocellular Carcinoma","PD-1 Inhibitor","Hepatic Arterial Infusion Chemotherapy",[26,35,39,43,46,31],"2025-02-05",{"date":108,"type":109},"2025-02-06","ACTUAL",{"date":111,"type":109},"2021-01-01",{"date":113,"type":98},"2025-12-30",{"name":5,"class":6},1]